Literature DB >> 22058311

The use of CRP within a clinical prediction algorithm for the differentiation of septic arthritis and transient synovitis in children.

R Singhal1, D C Perry, F N Khan, D Cohen, H L Stevenson, L A James, J S Sampath, C E Bruce.   

Abstract

Clinical prediction algorithms are used to differentiate transient synovitis from septic arthritis. These algorithms typically include the erythrocyte sedimentation rate (ESR), although in clinical practice measurement of the C-reactive protein (CRP) has largely replaced the ESR. We evaluated the use of CRP in a predictive algorithm. The records of 311 children with an effusion of the hip, which was confirmed on ultrasound, were reviewed (mean age 5.3 years (0.2 to 15.1)). Of these, 269 resolved without intervention and without long-term sequelae and were considered to have had transient synovitis. The remaining 42 underwent arthrotomy because of suspicion of septic arthritis. Infection was confirmed in 29 (18 had micro-organisms isolated and 11 had a high synovial fluid white cell count). In the remaining 13 no evidence of infection was found and they were also considered to have had transient synovitis. In total 29 hips were categorised as septic arthritis and 282 as transient synovitis. The temperature, weight-bearing status, peripheral white blood cell count and CRP was reviewed in each patient. A CRP > 20 mg/l was the strongest independent risk factor for septic arthritis (odds ratio 81.9, p < 0.001). A multivariable prediction model revealed that only two determinants (weight-bearing status and CRP > 20 mg/l) were independent in differentiating septic arthritis from transient synovitis. Individuals with neither predictor had a < 1% probability of septic arthritis, but those with both had a 74% probability of septic arthritis. A two-variable algorithm can therefore quantify the risk of septic arthritis, and is an excellent negative predictor.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22058311     DOI: 10.1302/0301-620X.93B11.26857

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  8 in total

1.  Reply to the Letter to the Editor: Another look: is there a flaw to current hip septic arthritis diagnostic algorithms?

Authors:  Chika Edward Uzoigwe
Journal:  Clin Orthop Relat Res       Date:  2013-10-22       Impact factor: 4.176

2.  Hip Synovial Fluid Cell Counts in Children From a Lyme Disease Endemic Area.

Authors:  Arianna H Dart; Kenneth A Michelson; Paul L Aronson; Aris C Garro; Thomas J Lee; Kimberly M Glerum; Peter A Nigrovic; Mininder S Kocher; Richard G Bachur; Lise E Nigrovic
Journal:  Pediatrics       Date:  2018-04-18       Impact factor: 7.124

3.  Another look: is there a flaw to current hip septic arthritis diagnostic algorithms?

Authors:  Chika Edward Uzoigwe
Journal:  Clin Orthop Relat Res       Date:  2013-08-28       Impact factor: 4.176

4.  Ewing's sarcoma of the pelvis: an unusual, but not to be missed, cause of an irritable hip.

Authors:  Partha Ray; Julekha Girach; Anish Pradip Sanghrajka
Journal:  BMJ Case Rep       Date:  2016-01-21

5.  The epidemiology of transient synovitis in Liverpool, UK.

Authors:  William D Harrison; A K Vooght; R Singhal; C E Bruce; D C Perry
Journal:  J Child Orthop       Date:  2014-01-22       Impact factor: 1.548

6.  Hip pain in the paediatric age group - transient synovitis versus septic arthritis.

Authors:  Gt Tay; M Ashik; B Tow; Kevin Bl Lim
Journal:  Malays Orthop J       Date:  2013-07

7.  Time to diagnosis in juvenile idiopathic arthritis: a french perspective.

Authors:  Laura Aoust; Linda Rossi-Semerano; Isabelle Koné-Paut; Perrine Dusser
Journal:  Orphanet J Rare Dis       Date:  2017-02-28       Impact factor: 4.123

8.  A prospective study of screening for musculoskeletal pathology in the child with a limp or pseudoparalysis using erythrocyte sedimentation rate, C-reactive protein and MRI.

Authors:  P D Mitchell; A Viswanath; N Obi; A Littlewood; M Latimer
Journal:  J Child Orthop       Date:  2018-08-01       Impact factor: 1.548

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.